NV3P.F NANOVIRICIDES NEW DL-01
- Market cap
- EUR 29.4M
- P/E
- -
- P/B
- 4.01x
- ROE
- -94.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is NV3P.F undervalued?
Graham numberThe Graham number of NANOVIRICIDES NEW DL-01 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NANOVIRICIDES NEW DL-01 fundamental analysis
No fundamental analysis for NANOVIRICIDES NEW DL-01 yet.
NANOVIRICIDES NEW DL-01 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NANOVIRICIDES NEW DL-01
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup a…
Full company profileNANOVIRICIDES NEW DL-01 financial statements
NANOVIRICIDES NEW DL-01 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -8.11M | -8.94M | -8.52M | -9.59M | -8.31M |
| EBITDA | -7.38M | -7.84M | -7.49M | -8.72M | -7.69M |
| Net Income | -8.11M | -8.59M | -8.29M | -9.47M | -8.22M |
| EPS | -0.70 | -0.73 | -0.63 | -0.57 | -0.36 |
| Balance Sheet | |||||
| Total Assets | 23.5M | 16.9M | 12.8M | 8.82M | 9.87M |
| Total Liabilities | 413K | 2.03M | 1.36M | 1.31M | 1.19M |
| Shareholders' Equity | 23.1M | 14.9M | 11.5M | 7.52M | 8.68M |
| Cash & Short-term Investments | 14.1M | 8.15M | 4.80M | 1.56M | 2.79M |
| Cash Flow | |||||
| Operating Cash Flow | -5.89M | -5.67M | -6.32M | -8.48M | -7.70M |
| Capital Expenditure | 324K | 152K | 157K | 57.0K | 84.3K |
| Free Cash Flow | -6.22M | -5.82M | -6.47M | -8.54M | -7.78M |
| Ratios | |||||
| ROE | -35.1% | -57.8% | -72.3% | -125.9% | -94.7% |
| ROA | -34.5% | -50.8% | -64.7% | -107.3% | -83.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
NANOVIRICIDES NEW DL-01 dividends
NANOVIRICIDES NEW DL-01 has not paid dividends in the last 6 fiscal years.
Last stock split: 1:3.5 on Sep 10, 2013.
Who owns NANOVIRICIDES NEW DL-01
- Insiders 2.49%
- Institutions 9.33%
- Public & others 88.18%
- Shares outstanding 25.5M
- Free float 24.9M
NANOVIRICIDES NEW DL-01 company profile
- Company name
- NANOVIRICIDES NEW DL-01
- Ticker
- NV3P.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Fiscal year end
- June
- Address
- 1 Controls Drive, Shelton, CT, United States, 06484
- Phone
- 203 937 6137
- Website
- nanoviricides.com
About NANOVIRICIDES NEW DL-01
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
NANOVIRICIDES NEW DL-01 management
2- Dr. Anil R. Diwan Ph.D.Executive Chairman, President, CEO & Secretary · born 1959
- Ms. Meeta R. Vyas B.S., M.B.A., SBCFO & Compliance Officer · born 1959